VTYX News and Press, Ventyx Biosciences Inc. From 05/14/23

2023-05-14 13:55:03 ET Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief M...

2023-05-11 16:14:02 ET Ventyx Biosciences press release ( NASDAQ: VTYX ): Q1 GAAP EPS of -$0.68 misses by $0.03 . For further details see: Ventyx Biosciences GAAP EPS of -$0.68 misses by $0.03

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is progressing, with topline data expe...

ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today anno...

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, tod...

2023-03-23 20:41:06 ET Ventyx Biosciences, Inc. (VTYX) Q4 2022 Earnings Conference Call March 24, 2023 04:30 p.m. ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chi...

2023-03-23 16:04:02 ET Ventyx Biosciences press release ( NASDAQ: VTYX ): Q4 GAAP EPS of -$0.62 beats by $0.02 . Cash, cash equivalents and marketable securities of $356.6 million at the end of 2022 plus an additional $48.4 million in net proceeds raised in Q1 2023 und...

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis (UC) is on track to complete e...

2023-03-21 09:28:28 ET Ventyx Biosciences ( NASDAQ: VTYX ) traded higher pre-market Tuesday after Wells Fargo initiated its coverage with an Overweight recommendation citing an attractive entry point ahead of multiple catalysts over the next 12 – 18 months. The comp...

2023-03-20 08:57:38 ET Summary Dan Loeb's 13F portfolio value increased from $5.53B to $5.97B this quarter. The number of positions decreased from 61 to 44. Third Point added American International Group, Microsoft, and International Flavors & Fragrances while dropping Cano He...